← Leaderboards
Margaret J Uprichard
Point Therapeutics, Inc.
$300,000
Attributed
$300,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2005–06$500K$375K$250K$125K$0
'05
'06
Funding mix
By agency
FDA$300,000 · 1
By mechanism
R01$300,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Clinical Trial Phase Ii”
- Lawrence Corey · Fred Hutchinson Cancer Center$421,688,762
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- Kimberly Smith · Ppd Development Lp$115,671,664
- Richard L Schilsky · University Of Chicago$114,474,127
- Philip J Disaia · University Of California Irvine$88,426,610
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$83,920,398
Research focus
Clinical Trial Phase IiDrug Screening /EvaluationMonoclonal AntibodyNeoplasm /Cancer Chemotherapy